Buy or sell guide
Should I Buy AZN Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for AstraZeneca PLC.
Updated 2026-05-06
Wall Street currently rates AZN buy with a 12-month price target of $211 (+16.4% upside). The sections below cover the bull case, key risks, and latest earnings context for AZN.
Wall Street
Buy41 analystsConsensus target
$211 target (+16.4%)Current price $181.24Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 2.4%Reported Wed Apr 29Wall Street verdict
Should I Buy AZN Stock? Here's What Analysts Think
41 analysts currently cover AZN. Below is their consensus rating, price target range, and implied upside.
According to 41 analysts, AstraZeneca PLC (AZN) is rated Buy with a consensus 12-month price target of $211 — representing 16% upside from today's price of $181. The bull case target is $216, the bear case is $206.
AZNBuy
From 41 analyst ratings- Current price
- $181.24
- Consensus Target
- $211 (+16.4% upside)
- Forward P/E
- 17.6x
- Coverage
- 41 analyst ratings
High target$216
Low target$206
At $181.24, the consensus setup implies +16.4% versus the 12-month target.
- 20 of 41 analysts lean Buy or Strong Buy, while 15 stay on Hold and 6 lean bearish.
- AZN trades at roughly 17.6x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $206 to $216, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for AZN right now.
Live commentary on X
What Analysts Are Saying About AstraZeneca PLC Right Now
Real posts from high-reach stock analysts mentioning AZN, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about AZN in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy AZN?
Is AZN a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for AZN before you decide whether to buy, hold, or sell.
Current setup
AZN beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Pipeline of DrugsAstraZeneca has over 20 Phase III readouts expected in 2026, including positive Q1 results for tozorakimab and Enhertu.
- Oncology Division GrowthThe oncology division contributes approximately 45% of revenues, supported by blockbuster drugs and a deep pipeline.
- Robust Financial PerformanceQ1 2026 revenues increased by 8% year-on-year, with operating profit rising 17% and guidance for mid-to-high single-digit revenue growth.
- Positive Analyst SentimentThe consensus rating is 'Moderate Buy', with price targets up to $236.65 by April 2027, indicating potential upside.
- Projected Revenue GrowthAnalysts project revenues to reach $80 billion annually by 2030, reflecting strong growth expectations.
Wall Street rates AZN buy, giving the bull case institutional backing from 41 analysts.
Watch Out For
What can break the setup quickly
- Patent Expiration RisksThe US patent expiry for Farxiga in 2026 is expected to cause revenue declines, with Brilinta already seeing a 65% drop due to generics.
- Pricing Pressure ConcernsUS drug pricing policies and China's Volume-Based Purchasing could impact future drug launches and profitability.
- Execution Risks in TrialsNot all Phase III trials may succeed, as evidenced by the Ceralasertib LATIFY failure, raising concerns about revenue generation.
- High Debt LevelsNet debt has risen to $25.9 billion, with a debt-to-equity ratio of 60.87%, indicating increased financial risk.
- Cautious Analyst OutlookSome analysts express caution regarding the catalyst path in early 2026, with a 'sell' rating from Deutsche Bank highlighting concerns.
Watch whether new negative commentary on AZN points to these structural risks or is simply reacting to short-term price moves.
AZN Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $2.58 vs $2.52 est.Beat 2.4%
- Revenue
- $15.3B vs $14.9B est.Beat 2.4%
Full AZN Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy AZN Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonAZN — Frequently Asked Questions
Quick answers to the most common questions about buying AZN stock.
Should I buy AZN stock right now?
Verdict
AZN has modest upside — analysts rate it "Buy" with a $211 target, implying +16.4% from today's $181.24. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy AZN?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +16.4% upside to the $211 target.
What is the price target for AZN stock?
Price Target
AZN's consensus 12-month price target is $211, set by 41 Wall Street analysts. The bull case high is $216 and the bear case low is $206. From the current price of $181.24, this implies +16.4% upside.
Is AZN overvalued or undervalued?
Valuation
AZN appears undervalued — the $211 consensus target is +16.4% above today's $181.24. It trades at a forward P/E of 17.6x. Targets range from $206 (bear) to $216 (bull), reflecting different assumptions about growth and margins.
Should I buy AZN before earnings?
Earnings
AZN reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $211 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about AZN stock?
Coverage
Of 41 analysts covering AstraZeneca PLC (AZN): 1 Strong Buy, 19 Buy, 15 Hold, 6 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $211 (range $206–$216). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying AZN stock?
Risks
6 of the 41 analysts covering AZN rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on AstraZeneca PLC.
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.